{"name":"AffyImmune Therapeutics, Inc.","slug":"affyimmune-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AIC100 CAR T Cells","genericName":"AIC100 CAR T Cells","slug":"aic100-car-t-cells","indication":"Relapsed or refractory B-cell lymphoma","status":"phase_1"}]}],"pipeline":[{"name":"AIC100 CAR T Cells","genericName":"AIC100 CAR T Cells","slug":"aic100-car-t-cells","phase":"phase_1","mechanism":"Chimeric antigen receptor T cells targeting CD19","indications":["Relapsed or refractory B-cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5LYW1kSmx3cWRvNVp0THNaRVJrc0VpMUk1aHdYSVJ3dFFpbnlsQXpVV1lMQkhSMWpreEJjN0p5cFRwbEIwQVRBeHc2NXBXVksxdVRUdUt6RmFWdlpaTVFn?oc=5","date":"2025-09-15","type":"pipeline","source":"nature.com","summary":"People - nature.com","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPQkE4QVZMRTF0VW5wYTFlTmFNNFBhQ1JZQ2JLRnNPSGtPMUk1eXRWdm94b3pZc1B3MjJ6dWF1TEw1SjhOT3RuLWRSNU1BLXphb2liQTgyd1RVV0IwM1h0SGhKdWI4ZnFWZUlEb05VNlFaMGp2Rm1SZ0xxbVUzaV9vb0IzejRjWDlMX3NUUmk5UEItX3llRDJJU09XWElGTE8yNDNkRlpXOEtLd2pfbnhGcA?oc=5","date":"2025-08-01","type":"regulatory","source":"endpoints.news","summary":"Novo Nordisk's shakeup goes beyond a new CEO; Former FDAer snags regulatory role at GSK - endpoints.news","headline":"Novo Nordisk's shakeup goes beyond a new CEO; Former FDAer snags regulatory role at GSK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOdG5HU0kwZUNwSWpYcl8wQmNEMGg1a2gya0lRN1c5SDFfWDUtZzU0ZTdtUEw2TXI2YzRpMG91NHJuYW9rZF9TUldVaHR1MU5GUkdndDF2THo1SHhna1RXXzJ1UVN2VWdqX1kxeU52dmlQeGJrd3QwZmktV3NYa3pzcjVBSTMtNGNPZU9YdHZyUXJnaFYxdlFtRElHazdzem5KMVZwY3F1WkRCMEd5eTE2b2NFNXZTMHhPT2dzc2pkLVNaYTBEdnF2OFJVbXpGM0d2eDVwSXhYMUxXcVEtT2IzaG9aYWZHLXkz?oc=5","date":"2025-01-06","type":"regulatory","source":"CRISPR Medicine News","summary":"Press Release Service: CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-T Therapies and Late-stage Clinical Trials that Could Reach Commercialization So","headline":"Press Release Service: CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNLXFjYkplTEJDNjFES3F4czBoSlFRdDY2RVRGNGVVTWZUUWlNcTlVZ2U2cFdfSXZYQ3g3UDhwSElDSTlfSmVBY2FZeHFtREt5N2VyN21fTk9PNnNoTFJYTXRJWlJDSENaSUkxeDdrLVozVS1kWnVlOUotV2ttYUpLRXAzemxGTU5DMDh2RVBXQ1p2QVE1UmlpaUVXZThOaG1jRnRSd0RRYkxmQzJOU3FtYXcwbTg?oc=5","date":"2024-11-25","type":"pipeline","source":"PR Newswire","summary":"AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer - PR Newswire","headline":"AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPUUNnUjdiZmZXSjVrb2hucVFoNERaLVkydUJZdjdtYmpySktBZ1NUWHlwWUc3ZzBRclRyQWJjaVBsZzJELXdUbTNNNW9SNmdFcHAzZzZMNnpSdnU0emVmc3VPM0pHVEcxU0U1OC1yR2VSd0Q5MlFXYUZ5dmlRN3JQVXg0OHhmcDgtUktTeQ?oc=5","date":"2024-11-25","type":"pipeline","source":"Contract Pharma","summary":"AffyImmune Names Chief Medical Officer - Contract Pharma","headline":"AffyImmune Names Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNRWFaLWJ0T1VwdzN1SlByOHpRVWdrczREVndxcXJnWjlpb0ptOGFLUDhwa0JVRWRyYlpGY0phd3h4ak1EVkdKY3o3Q0YxNlowMEp6aU40U1hpYV9NTFpWS1ZGX1pGRWFCdnY0WVdDalN0NDVKTTJlQko5UjRST2RJbkU1bGQ?oc=5","date":"2024-05-24","type":"pipeline","source":"pharmaphorum","summary":"ASCO: AffyImmune claims a first with CAR-T for solid tumours - pharmaphorum","headline":"ASCO: AffyImmune claims a first with CAR-T for solid tumours","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNR1hpT2gxamNHTVIwMWY2WEtWV1dMUzIxSWotb2FFak5yUHpaWVZHXzBpVFVJbkd5elpMWE9jWWxNUW4yVnBZLWg0WWFoMUk1S3dBVFFfMFJwMHZ3TGJsbUl1TVZMOHpzT01GRTQ2QmpxZExqQnVJeUJQYUp0U1pGM3d1N29vaTF4OHIxR2d3?oc=5","date":"2024-03-22","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech","headline":"Chutes & Ladders—Bayer undergoes leadership shake-up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNYTQxckZDV2R5OC10cjZmbzlrcEtvRy1Vc0ljWlNza2ltYlV0MklwaFRrM09hVHFnTElyeC1Wb0xuUUxTemZSX1pJUjU5dmJWZ0UwazU2NHdEOG1TRWo4ek9mNlRyQkFqRzl1QjBaRkpscW1XckxvX2ZDZnZ5TFdUZVM5WWN2el9fUVYtMS1WLW5xM050eko1MkRwS25sYTJmT0ZkaHRQLWd1NklLdWlz?oc=5","date":"2023-09-13","type":"trial","source":"Bloomberg.com","summary":"Ex-Goldman Banker Simone Song Uses Big Data to Beat Biotech’s Long Odds - Bloomberg.com","headline":"Ex-Goldman Banker Simone Song Uses Big Data to Beat Biotech’s Long Odds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE4zaXZJTE5Cb1czb2pYbENWVWpCREN6RVdRbVZRUU1oNkNIOFpES2FqYTNad2NNaXhXVnk1akdjMjdGS29jX1UtRmlpMlZTMTExbTc1dF90T0xoSUdseXJGRGQ0b2ZNLUtTQWpj?oc=5","date":"2023-03-02","type":"trial","source":"GuruFocus","summary":"Krystal Biotech Inc, Affyimmune Therapeutics Inc, Rocket Pharmaceuticals Inc and Iovance Biotherapeutics Inc at Endpoints Webinar on Moving CGTx Clinical Development- Panel Transcript - GuruFocus","headline":"Krystal Biotech Inc, Affyimmune Therapeutics Inc, Rocket Pharmaceuticals Inc and Iovance Biotherapeutics Inc at Endpoint","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNcnJuMXFYTlhmTjJWWXBLd09Ya3Rvdk1fWjdJWG5xMVlMSmZHSFZJS0ZaeVl0TFBtMmtiTGg0QkNoMXUzQjRrU1VRSFpIV0NBQjhuOHNESmpGTXpCVEo3Si10YzFVaDlpY0RDYnRBb1Z3eTVxbVhSTk1PeUp1N2xYRHRpcnBCVWNkMm1KT3cxejBaOXhhWnZDUnl3MDJGSGtvNElZTk8zWlVKZEpJNXZvVHYyTzI?oc=5","date":"2021-12-15","type":"pipeline","source":"Fierce Biotech","summary":"Biopharma charts progress in translating CAR-T cell therapies to solid cancers - Fierce Biotech","headline":"Biopharma charts progress in translating CAR-T cell therapies to solid cancers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}